Moderna COVID-19 Vaccine Data Bring Multivalent Vs. Monovalent Debate Into Focus

 
• By Alaric DeArment

Phase II/III data for mRNA-1273.211 showed superiority against variants of concern to the original Spikevax, but Moderna’s top competitor has questioned the need for multivalent approaches.

Moderna announced Phase II/III data for its bivalent mRNA-1273.211 vaccine candidate • Source: Alamy

More from COVID-19

More from Scrip